{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:13:15Z","timestamp":1785510795420,"version":"3.56.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Sports Act. Living"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the prevalence, patterns and substances of intravenous (IV) therapy among elite endurance athletes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional observational study<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were anonymously surveyed through a specially designed questionnaire. Responses to the questionnaire were received between October 2020 and January 2021. IV use of various medications and its association with sex, age, sporting discipline and competition tier was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 138 elite track and field athletes (73 men and 65 women) 56.5% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200978) reported IV administration of various drugs not prohibited by the World Anti-Doping Agency. Within this group, 18.8% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926) administered these drugs regularly and 37.7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200952) during the preparation for major competitions only competition. Actovegin (77.4%), phosphocreatine (64.5%), amino acids (58.1%), essentiale (57.0%), heptral (47.3%) and reamberin (44.1%) were most commonly used for this purpose. Comparison by competition level criterion revealed more frequent use of IV therapy by international level athletes compared to national level athletes (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02, OR 2.43 1.14\u20135.15). In addition, extra-level athletes were also significantly more likely to use amino acids (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016) and essentiale (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.024) compared to national-level athletes. There were no statistically significant differences in the prevalence of parenteral medication use between international and extra-level athletes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of IV therapy among elite track and field athletes appears to be relatively common based on self-reported data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fspor.2026.1810913","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:16:58Z","timestamp":1782127018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Frequency of intravenous therapy use in elite adult track and field athletes"],"prefix":"10.3389","volume":"8","author":[{"given":"Eduard","family":"Bezuglov","sequence":"first","affiliation":[{"name":"Department of Sports Medicine and Medical Rehabilitation, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Achkasov","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine and Medical Rehabilitation, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryland","family":"Morgans","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine and Medical Rehabilitation, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artemii","family":"Lazarev","sequence":"additional","affiliation":[{"name":"Northwest Health, Chesterton","place":["Chicago, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Talibov","sequence":"additional","affiliation":[{"name":"Department of Therapy, Clinical Pharmacology and Ambulance Care, Russian University of Medicine","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Kapralova","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine and Medical Rehabilitation, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Koneva","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine and Medical Rehabilitation, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiy","family":"Malyakin","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine and Medical Rehabilitation, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40279-014-0247-x","article-title":"Prevalence of doping use in elite sports: a review of numbers and methods","volume":"45","author":"De Hon","year":"2015","journal-title":"Sports Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1373\/clinchem.2010.156067","article-title":"Prevalence of blood doping in samples collected from elite track and field athletes","volume":"57","author":"Sottas","year":"2011","journal-title":"Clin Chem"},{"key":"B3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40279-017-0765-4","article-title":"Doping in two elite athletics competitions assessed by randomized-response surveys","volume":"48","author":"Ulrich","year":"2018","journal-title":"Sports Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/02701367.2020.1764469","article-title":"Gender differences in prevalence and patterns of dietary supplement use in elite athletes","volume":"92","author":"Aguilar-Navarro","year":"2021","journal-title":"Res Q Exerc Sport"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.3390\/nu14194109","article-title":"Prevalence of dietary supplement use among athletes worldwide: a scoping review","volume":"14","author":"Daher","year":"2022","journal-title":"Nutrients"},{"key":"B6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/19390211.2022.2056670","article-title":"Age drives the differences in dietary supplement use in endurance athletes: a cross-sectional analysis of cyclists, runners, and triathletes","volume":"20","author":"Graybeal","year":"2023","journal-title":"J Diet Suppl"},{"key":"B7","year":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/JSM.0b013e31820f3612","article-title":"Seventy-Five percent of national football league teams use pregame hyperhydration with intravenous fluid","volume":"21","author":"Fitzsimmons","year":"2011","journal-title":"Clin J Sport Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1136\/bjsports-2022-105883","article-title":"Rise of intravenous nutrition products among professional team sport athletes: reasons to be concerned?","volume":"56","author":"Lewis","year":"2022","journal-title":"Br J Sports Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1504\/IJBHR.2011.043414","article-title":"Measuring bias in self-reported data","volume":"2","author":"Rosenman","year":"2011","journal-title":"IJBHR"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.3389\/fpsyg.2019.02309","article-title":"Controlling for response biases in self-report scales: forced-choice vs. Psychometric modeling of Likert items","volume":"10","author":"Kreitchmann","year":"2019","journal-title":"Front Psychol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1249\/MSS.0000000000000568","article-title":"Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes","volume":"47","author":"Burden","year":"2015","journal-title":"Med Sci Sports Exerc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.csm.2010.03.007","article-title":"Exertional collapse in the runner: evaluation and management in fieldside and office-based settings","volume":"29","author":"Childress","year":"2010","journal-title":"Clin Sports Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1249\/MSS.0b013e3182a53594","article-title":"Intravenous iron supplementation in distance runners with low or suboptimal ferritin","volume":"46","author":"Garvican","year":"2014","journal-title":"Med Sci Sports Exerc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/JSM.0b013e31815eb0b5","article-title":"Hypernatremia and intravenous fluid resuscitation in collapsed ultramarathon runners","volume":"18","author":"Hew-Butler","year":"2008","journal-title":"Clin J Sport Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e108042","DOI":"10.1371\/journal.pone.0108042","article-title":"Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners","volume":"9","author":"Woods","year":"2014","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1249\/JSR.0b013e31829cdff2","article-title":"Creatine supplementation","volume":"12","author":"Hall","year":"2013","journal-title":"Curr Sports Med Rep"},{"key":"B18","first-page":"45","article-title":"Creatine and phosphocreatine: a review of their use in exercise and sport","volume":"32","author":"Clark","year":"1997","journal-title":"J Athl Train"},{"key":"B19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00421-007-0558-9","article-title":"Kinetics of creatine ingested as a food ingredient","volume":"102","author":"Deldicque","year":"2007","journal-title":"Eur J Appl Physiol"},{"key":"B20","first-page":"358","article-title":"Oral and intravenously administered amino acids produce similar effects on muscle protein synthesis in the elderly","volume":"6","author":"Rasmussen","year":"2002","journal-title":"J Nutr Health Aging"},{"key":"B21","first-page":"314","article-title":"[Adjuvant energy protection with reamberin in practice of intensive care and resuscitation: meta-analysis data about effectiveness (systematic review).]","volume":"61","author":"Mazina","year":"2016","journal-title":"Anesteziol Reanimatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1055\/s-0043-115738","article-title":"Comprehensive analytics of actovegin\u00ae and its effect on muscle cells","volume":"38","author":"Reichl","year":"2017","journal-title":"Int J Sports Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/17461391.2015.1130750","article-title":"Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle","volume":"16","author":"S\u00f8nderg\u00e5rd","year":"2016","journal-title":"Eur J Sport Sci"},{"key":"B24","first-page":"856","article-title":"Heptral (ademetionine) in patients with intrahepatic cholestasis in chronic liver disease due to non-alcoholic liver disease: results of a multicentre observational study in India","volume":"111","author":"Virukalpattigopalratnam","year":"2013","journal-title":"J Indian Med Assoc"},{"key":"B25","first-page":"82","article-title":"Experience in heptral treatment of diffuse liver diseases","volume":"70","author":"Gorbakov","year":"1998","journal-title":"Ter Arkh"},{"key":"B26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CEG.S96362","article-title":"Essential phospholipids in fatty liver: a scientific update","volume":"2016","author":"Gundermann","year":"2016"},{"key":"B27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/1941738112446285","article-title":"Intravenous fluid use in athletes","volume":"4","author":"Givan","year":"2012","journal-title":"Sports Health: A Multidisciplinary Approach"},{"key":"B28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.7748\/ns2007.09.22.1.44.c4613","article-title":"Peripheral intravenous cannulation: safe insertion and removal technique","volume":"22","author":"Ingram","year":"2007","journal-title":"Nurs Stand"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1001\/archinte.1993.00410140084010","article-title":"Effect of patient position on the incidence of vasovagal response to venous cannulation","volume":"153","author":"Rapp","year":"1993","journal-title":"Arch Intern Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/jocn.14760","article-title":"Incidence, severity and risk factors of peripheral intravenous cannula-induced complications: an observational prospective study","volume":"28","author":"Simin","year":"2019","journal-title":"J Clin Nurs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0002-9343(02)01163-4","article-title":"The epidemiology of peripheral vein infusion thrombophlebitis: a critical review","volume":"113","author":"Tagalakis","year":"2002","journal-title":"Am J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.52082\/jssm.2021.328","article-title":"Undeclared doping substances are highly prevalent in commercial sports nutrition supplements","volume":"20","author":"Duiven","year":"2021","journal-title":"jsportscimed"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/nu9101093","article-title":"Intended or unintended doping? A review of the presence of doping substances in dietary supplements used in sports","volume":"9","author":"Mart\u00ednez-Sanz","year":"2017","journal-title":"Nutrients"},{"key":"B34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pedn.2017.09.012","article-title":"Randomized trial evaluating the effectiveness of a leg crossing and muscle tensing technique on decreasing vasovagal symptoms among pediatric and young adult patients undergoing peripheral IV catheter insertion","volume":"38","author":"McIntyre-Patton","year":"2018","journal-title":"J Pediatr Nurs"}],"container-title":["Frontiers in Sports and Active Living"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fspor.2026.1810913\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:55:50Z","timestamp":1785509750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fspor.2026.1810913\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":34,"alternative-id":["10.3389\/fspor.2026.1810913"],"URL":"https:\/\/doi.org\/10.3389\/fspor.2026.1810913","relation":{},"ISSN":["2624-9367"],"issn-type":[{"value":"2624-9367","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1810913"}}